文献速递慢性静脉疾病静脉血栓栓塞

专用混合斜口支架治疗髂总静脉受压的通畅性与临床结局

Patency and Clinical Outcomes of a Dedicated, Self-Expanding, Hybrid Oblique Stent Used in the Treatment of Common Iliac Vein Compression.
PubMed 文献 · J Endovasc Ther · 2016-11-10

该研究基于Bern静脉支架登记数据库,纳入24例髂总静脉受压并接受sinus-Obliquus混合支架治疗且随访≥6个月的患者,平均随访10±3个月。Kaplan-Meier分析显示6个月一期通畅率92%(95%CI 71%–98%),10个月83%(95%CI 54%–95%),二次通畅率100%,全部患者临床改善,50%症状完全缓解。

要点

  • 专用混合斜口镍钛支架治疗髂总静脉受压早期一期通畅率良好,10个月为83%。
  • 支架血栓或再狭窄经再干预后二次通畅率达100%,全部患者临床改善。
  • 血栓后综合征患者Villalta评分下降6±6分(p=0.02),rVCSS下降3±1分(p=0.05)。

核心结论

  • 在髂总静脉受压患者中,斜口混合镍钛支架似可提供良好的早期通畅率和临床结局。

研究设计与样本

  • 回顾性登记数据库研究,检索Bern静脉支架登记库,纳入24例髂总静脉受压且支架治疗后随访至少6个月的患者;平均年龄39±18岁,20例为女性。
  • 其中10例为血栓后综合征,10例为导管导向治疗后急性髂股静脉血栓形成,4例为非血栓性髂静脉受压。
  • 主要治疗成功定义为静脉造影示顺行血流且狭窄<30%,并在治疗段探及自发性多普勒信号;支架通畅性用双功能超声评估。

主要发现

  • 全部患者均获得主要治疗成功,平均随访10±3个月。
  • Kaplan-Meier分析一期通畅率6个月为92%(95%CI 71%–98%),10个月为83%(95%CI 54%–95%)。
  • 3例有症状患者因早期和晚期支架血栓、另1例因支架内再狭窄接受再干预,二次通畅率为100%。
  • 末次随访时全部患者临床改善,50%报告症状完全缓解;血栓后综合征患者Villalta评分下降6±6分(p=0.02),rVCSS下降3±1分(p=0.05)。
  • 深静脉血栓患者中无一例进展为血栓后综合征。

关键数值与推荐

  • 主要治疗成功标准:静脉造影示顺行血流且狭窄<30%,治疗段探及自发性多普勒信号。
  • 临床结局采用Villalta临床症状评分和修订版静脉临床严重程度评分(rVCSS)在随访3、6、12个月评估。
  • 通畅性评估采用双功能超声,通畅率以Kaplan-Meier法估算。

临床怎么用

  • 对髂总静脉受压患者,可考虑使用专用混合斜口镍钛支架,并以双功能超声随访监测通畅性。
  • 支架血栓或再狭窄经再干预可获得较高二次通畅率,需关注早期和晚期支架血栓风险。
  • 血栓后综合征患者支架治疗后Villalta和rVCSS评分改善,可作为疗效评估指标。

局限性

  • 为单中心登记数据库的回顾性研究,样本量仅24例,随访时间平均10±3个月。
  • 缺乏对照组,无法与非专用支架或其他治疗策略直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the clinical outcomes of a dedicated hybrid oblique nitinol stent that has been specifically designed to treat common iliac vein compression. METHODS: The Bern Venous Stent Registry database was interrogated to identify all patients who had at least 6-month follow-up after treatment with the sinus-Obliquus hybrid stent for common iliac vein compression. The search identified 24 patients (mean age 39±18 years; 20 women) who matched the search criteria. Ten patients had postthrombotic syndrome (PTS), another 10 patients had acute iliofemoral thrombosis after catheter-directed therapy, and 4 patients had nonthrombotic iliac vein compression. Primary treatment success was defined as antegrade flow and stenosis <30% on venography and evidence of a spontaneous Doppler signal in the treated segment. Stent patency was assessed using duplex ultrasound. Clinical outcomes were evaluated using a clinical symptom score (Villalta) and the revised venous clinical severity score (rVCSS) at 3, 6, and 12 months in follow-up. RESULTS: Primary treatment success was achieved in all patients. Mean follow-up was 10±3 months. Primary patency estimates by Kaplan-Meier analysis were 92% at 6 months [95% confidence interval (CI) 71% to 98%] and 83% (95% CI 54% to 95%) at 10 months. Three symptomatic patients underwent reintervention for early and late stent thromboses and the third for in-stent restenosis, resulting in secondary patency of 100%. Overall, all patients had clinical improvement at the latest follow-up; 50% reported complete resolution of symptoms. In patients with PTS, the Villalta score decreased by 6±6 points (p=0.02) and the rVCSS score by 3±1 points (p=0.05). Among deep vein thrombosis patients, none developed PTS. CONCLUSION: In patients with common iliac vein compression, the oblique hybrid nitinol stent appears to provide excellent early patency and clinical outcomes.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Stuck AK, Kunz S, Baumgartner I, et al. Patency and Clinical Outcomes of a Dedicated, Self-Expanding, Hybrid Oblique Stent Used in the Treatment of Common Iliac Vein Compression. J Endovasc Ther. 2016. PMID: 27831483. doi:10.1177/1526602816676803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。